Eliciting Adverse Event Information Sample Clauses
The "Eliciting Adverse Event Information" clause defines the procedures and responsibilities for collecting information about any negative or unintended effects experienced by participants during a clinical trial or study. This clause typically outlines how investigators should question participants, document their responses, and report any adverse events to the appropriate regulatory bodies or sponsors. By establishing clear methods for gathering and recording this information, the clause ensures that potential risks are identified promptly, participant safety is monitored, and regulatory compliance is maintained throughout the study.
Eliciting Adverse Event Information. At every study visit, patients must be asked a standard, non-directed question, such as, “How have you been feeling since your last visit?” to elicit any medically related changes in their well-being. They may also be asked if they have been hospitalized, had any accidents, used any new medications, or changed concomitant medication regimens (including prescription drugs, over-the-counter medications, vitamins, herbal products, and minerals). Responses must be documented in the source documents. In addition to patient observations, AEs must be documented for any clinically significant diagnosis resulting from abnormal laboratory test values, physical examination findings, or ECG abnormalities, or from other documents that are relevant to patient safety.
Eliciting Adverse Event Information. The investigator is to report all directly observed adverse events and all adverse events spontaneously reported by the study subject. In addition, study subjects should be questioned by site personnel about adverse events at each clinic visit using a standard non-leading question, such as “Have you experienced anything new or different since your previous study visit?” Certain adverse events require prompt and specific action by the investigator in any clinical trial.